Gapping up
M&A news: TWGP +11.7% (ACP Re announced that ACP Re has received all regulatory approvals required in connection with its previously announced acquisition of Tower. ), CTSH +2.8% (to acquire TriZetto for $2.7 bln in cash), WHR +2.1% (receives written approval from the China Securities Regulatory Commission to acquire a 51% stake in Hefei Rongshida Sanyo Electric), VC +1.1% (may be a possible takeover target, Bloomberg real M&A column says)
Other news: RSH +17.6% (considering $585 mln financing package, also Hearing Suntrust analyst suggesting reasoning behind potential Amazon (AMZN) deal), OTIV +13.2% (extending last weeks gains), TAP +7.2% (in response to M&A stories in the space), HALO +5.9% (partner Baxter (BAX) receives FDA approval from HYQVIA for treatment of adults with primary immunodeficiency), AU+5.5% (Hearing speculation that company will not proceed with restructuring), BPOP +3.8% (positive Barrons mention), ATHM +3.6% (favorable commentary on Friday's Mad Money, Tiger Global Management discloses 18.5% passive stake), BUD +3.1% (in financing talks for SABMiller deal), MYL +2.5% (Mylan Labs signs agreement with Gilead (GILD) to accelerate access to hepatitis C treatments), BITA +2.5% (Tiger Global Management discloses 14.9% passive stake), TGTX +2.5% (announces special protocol assessment agreement with the FDA for its first phase 3 clinical trial of TG-1101), DEO +2.2% (in response to M&A stories in the space), TASR +2% (Columbus and Knoxville join major cities moving to AXON cameras and EVIDENCE.com; new body-worn camera programs launch in Argentina and United Arab Emirates), YHOO +1.8% (Alibaba (BABA) may increase IPO range amid high demand to above $70 from $60-66 prior, according to reports), MO +1.8% (co has a 26.9% voting interest in Sabmiller (SBMRY))
Analyst comments: WGO +5.2% (initiated with an Outperform at BMO Capital Mkts), PAY +1.8% (initiated with a Buy at Monness Crespi & Hardt), NOK +1.7% (upgraded to Outperform at Oppenheimer), AYI +1.6% (upgraded to Buy from Neutral at Goldman), ABX +0.9% (upgraded to Neutral from Underweight at HSBC Securities)
M&A news: TWGP +11.7% (ACP Re announced that ACP Re has received all regulatory approvals required in connection with its previously announced acquisition of Tower. ), CTSH +2.8% (to acquire TriZetto for $2.7 bln in cash), WHR +2.1% (receives written approval from the China Securities Regulatory Commission to acquire a 51% stake in Hefei Rongshida Sanyo Electric), VC +1.1% (may be a possible takeover target, Bloomberg real M&A column says)
Other news: RSH +17.6% (considering $585 mln financing package, also Hearing Suntrust analyst suggesting reasoning behind potential Amazon (AMZN) deal), OTIV +13.2% (extending last weeks gains), TAP +7.2% (in response to M&A stories in the space), HALO +5.9% (partner Baxter (BAX) receives FDA approval from HYQVIA for treatment of adults with primary immunodeficiency), AU+5.5% (Hearing speculation that company will not proceed with restructuring), BPOP +3.8% (positive Barrons mention), ATHM +3.6% (favorable commentary on Friday's Mad Money, Tiger Global Management discloses 18.5% passive stake), BUD +3.1% (in financing talks for SABMiller deal), MYL +2.5% (Mylan Labs signs agreement with Gilead (GILD) to accelerate access to hepatitis C treatments), BITA +2.5% (Tiger Global Management discloses 14.9% passive stake), TGTX +2.5% (announces special protocol assessment agreement with the FDA for its first phase 3 clinical trial of TG-1101), DEO +2.2% (in response to M&A stories in the space), TASR +2% (Columbus and Knoxville join major cities moving to AXON cameras and EVIDENCE.com; new body-worn camera programs launch in Argentina and United Arab Emirates), YHOO +1.8% (Alibaba (BABA) may increase IPO range amid high demand to above $70 from $60-66 prior, according to reports), MO +1.8% (co has a 26.9% voting interest in Sabmiller (SBMRY))
Analyst comments: WGO +5.2% (initiated with an Outperform at BMO Capital Mkts), PAY +1.8% (initiated with a Buy at Monness Crespi & Hardt), NOK +1.7% (upgraded to Outperform at Oppenheimer), AYI +1.6% (upgraded to Buy from Neutral at Goldman), ABX +0.9% (upgraded to Neutral from Underweight at HSBC Securities)